Aetna to administer the gene therapy benefit for all PEBTF employees

Gene therapy drugs are expensive and require very specific care. PEBTF has contracted with Aetna to provide a consistent and comprehensive offering for members who are eligible for this benefit.

Starting Wednesday, Jan. 1, 2025, Aetna will administer the gene therapy benefit for all PEBTF employees enrolled in 1 of their 3 medical plan options. Aetna will provide coverage for the gene therapy medication along with a defined episode of care that is specific to the medication.

Contact Aetna at 833-398-0650 for clarification and details on what is covered.

Medications included in the PEBTF gene therapy benefit administered by Aetna

The following medications are currently included in the gene therapy benefit administered by Aetna. This list is subject to revisions and other medications may be added.

• Elevidys (delandistrogene moxeparvovec-roki) for Duchenne muscular dystrophy (DMD)

• Hemgenix (etranacogene dezaparvovec) for hemophilia B

• Luxturna (voretigene neparvovec-rzyl) for inherited retinal dystrophy (RPE65)

• Roctavian (valoctocogene roxaparvovec) for hemophilia A in adults

• Skysona (elivaldogene autotemcel) for cerebral adrenoleukodystrophy (CALD)

• Spinraza (nusinersen) for spinal muscular atrophy (SMA)

• Zolgensma (onasemnogene abeparvovec-xioi) for spinal muscular atrophy (SMA)

• Zynteglo (betibeglogene autotemcel) for beta-thalassemia

• Casgevy (beta-thalassemia) for beta-thalassemia

• Casgevy (exagamglogene autotemcel) for sickle cell disease

• Lyfgenia (lovotibeglogene autotemcel) for sickle cell disease

• Lenmeldy (atidarsagene autotemcel) for juvenile metachromatic leukodystrophy (MLD)

• BeqVez (fidanacogene elaparvovec) for hemophilia B